172 related articles for article (PubMed ID: 18308516)
1. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin.
Fujimura S; Watanabe A; Fuse K; Kikuchi T; Gomi K; Tokue Y
Int J Antimicrob Agents; 2008 Apr; 31(4):391-2. PubMed ID: 18308516
[No Abstract] [Full Text] [Related]
2. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
Kotlus BS; Wymbs RA; Vellozzi EM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):726-9. PubMed ID: 17056356
[TBL] [Abstract][Full Text] [Related]
3. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
[TBL] [Abstract][Full Text] [Related]
4. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.
Khosrovaneh A; Riederer K; Saeed S; Tabriz MS; Shah AR; Hanna MM; Sharma M; Johnson LB; Fakih MG; Khatib R
Clin Infect Dis; 2004 May; 38(9):1328-30. PubMed ID: 15127350
[TBL] [Abstract][Full Text] [Related]
5. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada.
Webster D; Rennie RP; Brosnikoff CL; Chui L; Brown C
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):177-81. PubMed ID: 16938420
[TBL] [Abstract][Full Text] [Related]
6. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
[TBL] [Abstract][Full Text] [Related]
7. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
8. Two heterogeneously vancomycin-intermediate clinical isolates of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in a Turkish university hospital: brief report of a surveillance study.
Torun MM; Bahar H; Demirci M; Altaş K; Bağdatli Y; Kocazeybek B; Kapi M; Hiramatsu K
Int J Antimicrob Agents; 2005 Dec; 26(6):508-10. PubMed ID: 16256313
[No Abstract] [Full Text] [Related]
9. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
[TBL] [Abstract][Full Text] [Related]
10. [The change in sensitivity of methicillin-resistant Staphylococcus aureus to vancomycin].
Ma Y; Chen H; Yao L; Li J; Zhang L; Hu C; Jin S
Zhonghua Nei Ke Za Zhi; 2002 Jan; 41(1):31-3. PubMed ID: 11940294
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
[TBL] [Abstract][Full Text] [Related]
12. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin minimum inhibitory concentration as a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia: a second look.
Porath AD; Brooks GD
Clin Infect Dis; 2008 May; 46(9):1483-4; author reply 1484-5. PubMed ID: 18419464
[No Abstract] [Full Text] [Related]
14. Design and synthesis of benzenesulfonanilides active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
Namba K; Zheng X; Motoshima K; Kobayashi H; Tai A; Takahashi E; Sasaki K; Okamoto K; Kakuta H
Bioorg Med Chem; 2008 Jun; 16(11):6131-44. PubMed ID: 18468909
[TBL] [Abstract][Full Text] [Related]
15. Nosocomial methicillin--resistant Staphylococcus aureus with reduced susceptibility to vancomycin.
Bhat G; Kamath S; Hussain A
Indian J Pathol Microbiol; 2006 Apr; 49(2):311-2. PubMed ID: 16933753
[No Abstract] [Full Text] [Related]
16. The effects of antibiotics combined with natural polyphenols against clinical methicillin-resistant Staphylococcus aureus (MRSA).
Lin RD; Chin YP; Hou WC; Lee MH
Planta Med; 2008 Jun; 74(8):840-6. PubMed ID: 18546080
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model.
Hamel A; Caillon J; Jacqueline C; Batard E; Potel G
Int J Antimicrob Agents; 2008 Feb; 31(2):158-60. PubMed ID: 18006281
[TBL] [Abstract][Full Text] [Related]
18. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis.
Bakri FG; Al-Hommos NA; Shehabi A; Naffa RG; Cui L; Hiramatsu K
Scand J Infect Dis; 2007; 39(5):457-60. PubMed ID: 17464871
[TBL] [Abstract][Full Text] [Related]
19. [Methicillin-resistant Staphylococcus aureus bacteremia. Predictor factors for an isolate with a vancomycin minimal inhibitory concentration > or =2 mg/l].
Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
Rev Esp Quimioter; 2008 Jun; 21(2):93-8. PubMed ID: 18509768
[TBL] [Abstract][Full Text] [Related]
20. The emergence of mupirocin resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Trinidad: a first report.
Orrett FA
Jpn J Infect Dis; 2008 Mar; 61(2):107-10. PubMed ID: 18362397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
